First-ever in-person PPI panel meeting for @lrcg.bsky.social @newcastleuni.bsky.social Great discussions with patients & families on ALL risk, AI in treatment, & reducing therapy. Lab tour highlight: lab coats on & excitement all around Part of BIOINFORM — @cancerresearchuk.org #Research #ALL

At #𝐈𝐂𝐊𝐒𝐇2026 in Seoul!🩸 @avmoorman.bsky.social is presenting on integrating Genetics & MRD in Acute Lymphoblastic Leukaemia🧬 🎯 Goal: Subtype-specific MRD thresholds to reduce over-treatment. 🚀 Future: Flexible risk algorithms to support novel therapies. #Leukaemia #PrecisionMedicine #Hematology

Proud to see @lrcg.bsky.social contribute to this global study in @nature.com(𝘕𝘢𝘵. 𝘊𝘰𝘮𝘮𝘶𝘯). We shared data to help refine AI that predicts leukemia subtypes from routine lab results, aiming to close global health diagnostic gaps🩸🌍 Read: doi.org/10.1038/s414... #Leukemia #AI #NewcastleUni

Great to be at the Annual Conference of @cclguk.bsky.social in Manchester. Prof. @avmoorman.bsky.social shared how the VIVO Biobank supports acute leukaemia research, highlighting key research from @lrcg.bsky.social, including the UKALL CNA profile in the ALLTogether trial.🧬🤝

𝑯𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒊𝒏𝒈 𝑩-𝒄𝒆𝒍𝒍 𝑨𝒄𝒖𝒕𝒆 𝑳𝒚𝒎𝒑𝒉𝒐𝒃𝒍𝒂𝒔𝒕𝒊𝒄 𝑳𝒆𝒖𝒌𝒂𝒆𝒎𝒊𝒂 (𝑩-𝑨𝑳𝑳) 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉🧬 Our group lead @avmoorman.bsky.social presented on risk stratification in B-ALL at the International ALL Assembly, sponsored by @amgen.bsky.social. Great opportunity to share our work with the international research community.

Excited to share our evaluation of the TALLSorts classifier!🧬 Our research letter validates its utility against standard DNA methods for paediatric T-ALL, demonstrating high concordance✅ Published now in British Journal of Haematology @wiley.com. Read here: onlinelibrary.wiley.com/doi/10.1111/...

Sharing a great 𝐏𝐡𝐃 𝐒𝐭𝐮𝐝𝐞𝐧𝐭𝐬𝐡𝐢𝐩 opportunity in 𝐁𝐢𝐨𝐬𝐞𝐧𝐬𝐨𝐫 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠. This multidisciplinary project focuses on developing next-generation biosensors for cancer monitoring and offers full funding for up to four years. Click for more information: www.ncl.ac.uk/postgraduate...

We’re proud to see our Prof Christine Harrison featured speaking with His Royal Highness The Duke of Kent during one of his visits to @newcastleuni.bsky.social. We join @bloodcanceruk.bsky.social in wishing His Royal Highness a very happy 90th birthday 🎉🎂 and thanking him for his support.

Last month in Madrid, the ALLTogether1 trial brought Europe’s teams roundtable. @avmoorman.bsky.social and other LRCG members shared genetics work to sort risk better and tailor treatment in ALL. Days like this remind us: good collaboration turns into patient impact. @newcastleuni.bsky.social

From the North East: a cancer survivor who became a doctor - proof that resilience + research change lives. With CRUK’s £4.1m boost to @newcastleuni.bsky.social, LRCG is excited to turn hope into outcomes. To the individual: your courage lifts us all. Read at www.chroniclelive.co.uk/news/north-e...

BIOINFORM (£2.7m @crukpolicy.bsky.social project) will: build CRISTAL (shared clinical/genomic data portal), develop AI risk tools to guide therapy, study new genetic changes in ALL, and map the genomics of childhood AML — so each patient gets the most effective, least toxic treatment.

Exciting milestone as we held BIOINFORM project kick-off at @newcastleuni.bsky.social, funded by @crukpolicy.bsky.social. The day began with presentations tracing the history of LRCG and introducing the different work packages that will drive the BIOINFORM project forward. @avmoorman.bsky.social